Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 22,169 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: control 2 Clear all
Completed Phase 2 Interventional Results available

Long-Term Study of Nitisinone to Treat Alkaptonuria

NCT00107783
View directory record Official record
Conditions
Alkaptonuria
Interventions
Nitisinone (NTBC)
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Alaska Native People to Quit Smoking

NCT03645941
View directory record Official record
Conditions
Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Smoking Cessation, Smoking, Cigarette, Smoking, Tobacco, Smoking
Interventions
Facebook Group
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 23, 2026, 2:16 PM EDT
Withdrawn Phase 4 Interventional

Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty

NCT06333522
View directory record Official record
Conditions
Arthrofibrosis of Knee
Interventions
Losartan
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

NCT04226131
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Controls
Interventions
Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment
Other
Lead sponsor
Duke University
Other
Eligibility
25 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

NCT04565353
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu shot text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
74,811 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Danville, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Not applicable Interventional

Advanced Heart Care at Home

NCT03724695
View directory record Official record
Conditions
Palliative Care, Heart Failure, Health Care Utilization, Quality Improvement
Interventions
Clinician nudge or opt out approach for AHCAH liaison visit
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

NCT01396239
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AVI-4658 (Eteplirsen), Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 13 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study Of Increasing Oral Doses Of PF-04634817

NCT01098877
View directory record Official record
Conditions
Healthy
Interventions
PF-04634817 Placebo, PF-04634817
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

NCT03674177
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 1 Interventional

A Study of LY3471851 in Participants With Psoriasis

NCT04119557
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, LY3471851
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
North Little Rock, Arkansas • Encinitas, California • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

NCT05080660
View directory record Official record
Conditions
Osteoarthritis, Osteo Arthritis Knee
Interventions
LY3526318, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Chandler, Arizona • Glendale, Arizona • Tempe, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab, MTX, placebo adalimumab, placebo MTX
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

NCT00113620
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
Neurodex
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
44
States / cities
Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 23, 2026, 2:16 PM EDT
Not listed Not applicable Interventional

NIH Release/Relock Socket

NCT04305782
View directory record Official record
Conditions
Lower Limb Amputation Below Knee (Injury)
Interventions
Release/Relock Socket - In Lab, Release/Relock Socket - Out of Lab, Release/Relock Socket & Control
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

NCT00765882
View directory record Official record
Conditions
Chronic Constipation
Interventions
Linaclotide 290 micrograms, Linaclotide 145 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 2:16 PM EDT
Recruiting Not applicable Interventional

Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes

NCT05893927
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Education, Lifestyle Modification
Interventions
Diabetes education web site application
Other
Lead sponsor
The Reading Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

NCT00914966
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 inhibitor (human) [C1 INH]
Biological
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Wheaton, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622
View directory record Official record
Conditions
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
Olaparib, Physician's choice chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
42
States / cities
San Diego, California • Santa Rosa, California • Whittier, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 2:16 PM EDT
Terminated Phase 2 Interventional Results available

A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.

NCT05524051
View directory record Official record
Conditions
Acute Kidney Injury Following Cardiac Surgery
Interventions
TIN816, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 100 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 2:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dietary and Cognitive Effects of Food Ads Posted by TikTok Influencers

NCT05777486
View directory record Official record
Conditions
Calorie Consumption
Interventions
TikTok Ads - With Food, TikTok Ads - Without Food
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
10 Years to 13 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 2:16 PM EDT
Enrolling by invitation No phase listed Observational

Global Utilization And Registry Database for Improved heArt preservatioN

NCT04141605
View directory record Official record
Conditions
Heart Diseases, Heart Failure, Heart Defects, Congenital
Interventions
SherpaPak Cardiac Transport System
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
17
States / cities
Stanford, California • Washington D.C., District of Columbia • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 2:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nutritional Intervention for Age-related Muscular Function and Strength Losses

NCT00874575
View directory record Official record
Conditions
Muscle Strength, Sarcopenia
Interventions
Placebo, Vitamin D, Beta-hydroxy-Beta-methylbutyrate, Beta-hydroxy-Beta-methylbutyrate and Vitamin D
Dietary Supplement · Drug
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
60 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Ames, Iowa • Brookings, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 23, 2026, 2:16 PM EDT